MiR155 Deficiency Reduces Myofibroblast Density but Fails to Improve Cardiac Function After Myocardial Infarction in Dyslipidemic Mouse Model

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jun 2

PMID 34067440

Citations 6

Authors

David Schumacher

Adelina Curaj

Sakine Simsekyilmaz

Andreas Schober

Elisa A Liehn

Sebastian F Mause

Affiliations

Soon will be listed here.

Abstract

Myocardial infarction remains the most common cause of heart failure with adverse remodeling. MicroRNA (miR)155 is upregulated following myocardial infarction and represents a relevant regulatory factor for cardiac remodeling by engagement in cardiac inflammation, fibrosis and cardiomyocyte hypertrophy. Here, we investigated the role of miR155 in cardiac remodeling and dysfunction following myocardial infarction in a dyslipidemic mouse model. Myocardial infarction was induced in dyslipidemic apolipoprotein E-deficient (ApoE) mice with and without additional miR155 knockout by ligation of the LAD. Four weeks later, echocardiography was performed to assess left ventricular (LV) dimensions and function, and mice were subsequently sacrificed for histological analysis. Echocardiography revealed no difference in LV ejection fractions, LV mass and LV volumes between ApoE and ApoE/miR155 mice. Histology confirmed comparable infarction size and unaltered neoangiogenesis in the myocardial scar. Notably, myofibroblast density was significantly decreased in ApoE/miR155 mice compared to the control, but no difference was observed for total collagen deposition. Our findings reveal that genetic depletion of miR155 in a dyslipidemic mouse model of myocardial infarction does not reduce infarction size and consecutive heart failure but does decrease myofibroblast density in the post-ischemic scar.

Citing Articles

Noncoding RNAs and Cardiac Fibrosis.

Wu C, Bao S, Li R, Sun H, Peng Y Rev Cardiovasc Med. 2024; 24(2):63.

PMID: 39077397 PMC: 11273127. DOI: 10.31083/j.rcm2402063.

The Role of ncRNAs in Cardiac Infarction and Regeneration.

Cano-Carrillo S, Lozano-Velasco E, Castillo-Casas J, Sanchez-Fernandez C, Franco D J Cardiovasc Dev Dis. 2023; 10(3).

PMID: 36975887 PMC: 10052289. DOI: 10.3390/jcdd10030123.

Novel Biomarkers of Atherosclerotic Vascular Disease-Latest Insights in the Research Field.

Adam C, Salaru D, Prisacariu C, Marcu D, Sascau R, Statescu C Int J Mol Sci. 2022; 23(9).

PMID: 35563387 PMC: 9103799. DOI: 10.3390/ijms23094998.

MiR-410-3p facilitates Angiotensin II-induced cardiac hypertrophy by targeting Smad7.

Jia G, Liang C, Li W, Dai H Bioengineered. 2021; 13(1):119-127.

PMID: 34951337 PMC: 8805929. DOI: 10.1080/21655979.2021.2009968.

Heart function assessment during aging in apolipoprotein E knock-out mice.

Liehn E, Lupan A, Diaconu R, Ioana M, Streata I, Manole C Discoveries (Craiova). 2021; 9(3):e136.

PMID: 34816004 PMC: 8605688. DOI: 10.15190/d.2021.15.

References

Wei Y, Yan X, Yan L, Hu F, Ma W, Wang Y . Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling. Mol Med Rep. 2017; 16(5):7287-7296. PMC: 5865857. DOI: 10.3892/mmr.2017.7584. View

Cao R, Li Q, Miao Y, Zhang Y, Yuan W, Fan L . The Emerging Role of MicroRNA-155 in Cardiovascular Diseases. Biomed Res Int. 2016; 2016:9869208. PMC: 5149600. DOI: 10.1155/2016/9869208. View

Guo J, Liu H, Sun C, Yan X, Hu J, Yu J . MicroRNA-155 Promotes Myocardial Infarction-Induced Apoptosis by Targeting RNA-Binding Protein QKI. Oxid Med Cell Longev. 2019; 2019:4579806. PMC: 6525929. DOI: 10.1155/2019/4579806. View

Kazimierczyk E, Eljaszewicz A, Zembko P, Tarasiuk E, Rusak M, Kulczynska-Przybik A . The relationships among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute myocardial infarction. Pharmacol Rep. 2018; 71(1):73-81. DOI: 10.1016/j.pharep.2018.09.007. View

Scarlatescu A, Micheu M, Popa-Fotea N, Dorobantu M . MicroRNAs in Acute ST Elevation Myocardial Infarction-A New Tool for Diagnosis and Prognosis: Therapeutic Implications. Int J Mol Sci. 2021; 22(9). PMC: 8124280. DOI: 10.3390/ijms22094799. View

Eissa M, Artlett C . The MicroRNA miR-155 Is Essential in Fibrosis. Noncoding RNA. 2019; 5(1). PMC: 6468348. DOI: 10.3390/ncrna5010023. View

Wang T, Wu C, Chen W, Lee C, Chen M, Liau C . Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. Am J Cardiol. 1998; 81(5):531-7. DOI: 10.1016/s0002-9149(97)00974-0. View

Yu H, Xu W, Gong F, Chi B, Chen J, Zhou L . MicroRNA-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL. Exp Ther Med. 2017; 14(5):4053-4060. PMC: 5658697. DOI: 10.3892/etm.2017.5085. View

Gangwar R, Rajagopalan S, Natarajan R, Deiuliis J . Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics. Am J Hypertens. 2017; 31(2):150-165. PMC: 5861558. DOI: 10.1093/ajh/hpx197. View

10.

Heymans S, Corsten M, Verhesen W, Carai P, van Leeuwen R, Custers K . Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013; 128(13):1420-32. DOI: 10.1161/CIRCULATIONAHA.112.001357. View

11.

Van Rooij E, Olson E . MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11(11):860-72. PMC: 6813819. DOI: 10.1038/nrd3864. View

12.

Wehbe N, Nasser S, Pintus G, Badran A, Eid A, Baydoun E . MicroRNAs in Cardiac Hypertrophy. Int J Mol Sci. 2019; 20(19). PMC: 6801828. DOI: 10.3390/ijms20194714. View

13.

Schumacher D, Alampour-Rajabi S, Ponomariov V, Curaj A, Wu Z, Staudt M . Cardiac FGF23: new insights into the role and function of FGF23 after acute myocardial infarction. Cardiovasc Pathol. 2019; 40:47-54. DOI: 10.1016/j.carpath.2019.02.001. View

14.

Curaj A, Schumacher D, Rusu M, Staudt M, Li X, Simsekyilmaz S . Neutrophils Modulate Fibroblast Function and Promote Healing and Scar Formation after Murine Myocardial Infarction. Int J Mol Sci. 2020; 21(10). PMC: 7279328. DOI: 10.3390/ijms21103685. View

15.

Welten S, Goossens E, Quax P, Nossent A . The multifactorial nature of microRNAs in vascular remodelling. Cardiovasc Res. 2016; 110(1):6-22. DOI: 10.1093/cvr/cvw039. View

16.

Tao L, Bei Y, Zhou Y, Xiao J, Li X . Non-coding RNAs in cardiac regeneration. Oncotarget. 2015; 6(40):42613-22. PMC: 4767457. DOI: 10.18632/oncotarget.6073. View

17.

Zhang B, Li B, Qin F, Bai F, Sun C, Liu Q . Expression of serum microRNA-155 and its clinical importance in patients with heart failure after myocardial infarction. J Int Med Res. 2019; 47(12):6294-6302. PMC: 7045684. DOI: 10.1177/0300060519882583. View

18.

Curaj A, Simsekyilmaz S, Staudt M, Liehn E . Minimal invasive surgical procedure of inducing myocardial infarction in mice. J Vis Exp. 2015; (99):e52197. PMC: 4542456. DOI: 10.3791/52197. View

19.

Hu J, Huang C, Rao P, Cao G, Zhang Y, Zhou J . MicroRNA-155 inhibition attenuates endoplasmic reticulum stress-induced cardiomyocyte apoptosis following myocardial infarction via reducing macrophage inflammation. Eur J Pharmacol. 2019; 857:172449. DOI: 10.1016/j.ejphar.2019.172449. View

20.

Schumacher D, Curaj A, Staudt M, Cordes F, Dumitrascu A, Rolles B . Phosphatidylserine Supplementation as a Novel Strategy for Reducing Myocardial Infarct Size and Preventing Adverse Left Ventricular Remodeling. Int J Mol Sci. 2021; 22(9). PMC: 8122843. DOI: 10.3390/ijms22094401. View